Related Experiment Video
Updated: Aug 17, 2026
Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
Inhibition of miR-25 Ameliorates Cardiac Dysfunction and Fibrosis by Restoring Krüppel-like Factor 4 Expression
Cholong Lee1, Sunghye Cho1, Dongtak Jeong1
1Department of Medicinal & Life Science, College of Science and Convergence Technology, Hanyang University-ERICA, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan 15588, Republic of Korea.
Insights
Inhibiting miR-25 improves heart function and reduces fibrosis in cardiac hypertrophy by restoring SERCA2a and KLF4 expression. This dual action offers a promising therapeutic strategy for hypertensive heart diseases.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Fibrosis Research
Background:
- Cardiac hypertrophy, a response to hypertension, can lead to impaired calcium handling, dysfunction, and fibrosis.
- Previous work identified miR-25 regulating SERCA2a, improving cardiac function and reducing fibrosis upon inhibition.
- The exact mechanism by which miR-25 inhibition reduces cardiac fibrosis remained unclear.
Purpose of the Study:
- To investigate additional targets of miR-25 involved in regulating cardiac fibrosis.
- To elucidate the precise mechanism of miR-25's role in cardiac fibrosis.
- To evaluate the therapeutic potential of miR-25 inhibition in hypertensive heart disease models.
Main Methods:
- In silico analysis to identify potential miR-25 targets.
- Experimental validation of miR-25 targeting Krüppel-like factor 4 (KLF4).
- Assessment of miR-25 inhibitor efficacy in Angiotensin II-induced cardiac dysfunction and fibrosis models.
Main Results:
- Krüppel-like factor 4 (KLF4) was identified as a direct target of miR-25.
- Angiotensin II treatment reduced KLF4 expression, while miR-25 inhibition restored it.
- miR-25 inhibition alleviated Angiotensin II-induced cardiac dysfunction, fibrosis, and inflammation.
Conclusions:
- miR-25 inhibition ameliorates cardiac hypertrophy by restoring both SERCA2a and KLF4 expression.
- Restoring KLF4 expression contributes to the anti-fibrotic effects of miR-25 inhibition.
- Targeting miR-25 presents a potential therapeutic avenue for hypertensive heart diseases.
Abstract:
Cardiac hypertrophy is an adaptive response to various pathological insults, including hypertension. However, sustained hypertrophy can cause impaired calcium regulation, cardiac dysfunction, and remodeling, accompanied by cardiac fibrosis. Our previous study identified miR-25 as a regulator of SERCA2a, and found that the inhibition of miR-25 improved cardiac function and reduced fibrosis by restoring SERCA2a expression in a murine heart failure model. However, the precise mechanism underlying the reduction in fibrosis following miR-25 inhibition remains unclear. Therefore, we postulate that miR-25 may have additional targets that contribute to regulating cardiac fibrosis. Using in silico analysis, Krüppel-like factor 4 (KLF4) was identified as an additional target of miR-25. Further experiments confirmed that KLF4 was directly targeted by miR-25 and that its expression was reduced by long-term treatment with Angiotensin II, a major hypertrophic inducer. Subsequently, treatment with an miR-25 inhibitor alleviated the cardiac dysfunction, fibrosis, and inflammation induced by Angiotensin II (Ang II). These findings indicate that inhibiting miR-25 not only enhances calcium cycling and cardiac function via SERCA2a restoration but also reduces fibrosis by restoring KLF4 expression. Therefore, targeting miR-25 may be a promising therapeutic strategy for treating hypertensive heart diseases.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
